Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2012

View Archived Issues

First patient dosed in phase II ELND-005 trial in bipolar disorder

Pathophysiological changes occur years before Alzheimer's disease symptoms develop

Allergan designs new FPRL1 ligands

Novel peptides for skin disorders disclosed by OrganoBalance

Takeda presents novel inhibitors of ACC2

Washington University presents new PET/SPECT imaging agents

Novel bacterial efflux pump inhibitors patented by Rempex Pharmaceuticals

Amgen presents novel beta-secretase inhibitors

Astellas Pharma discloses new 5-HT5A receptor ligands

AZD-9708 may have potential for obstructive airways diseases

Abilify filed in Japan as adjunctive treatment for major depressive disorder

CB2 receptor agonist proves useful for the treatment of erectile dysfunction

Mechanism of action of epelsiban besilate further elucidated

NeuroSearch transfers Janssen research collaboration agreement to Aniona

Phase I/II data suggest transrectal administration of PRX-302 is well tolerated in BPH

Janssen-Cilag submits European MAA for bedaquiline

VLST licenses CP-870893 from Pfizer

Oxis Turbuhaler launched in Japan

Bristol-Myers Squibb profiles novel MCH1 receptor antagonist

Novo Nordisk gives update on approval of insulin degludec in Japan

TB Alliance advances development of antitubercular nitroimidazoles

Companies seek additional indication approval for proton pump inhibitors

Gilead presents data on GS-9669 for HCV infection

Quest Diagnostics launches molecular cervical cancer test

NanoViricides reports findings from animal study of oral FluCide program

FDA approves Xtandi for metastatic castration-resistant prostate cancer

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...